Micro Developing Active

LLY GLP-1 特许经营增长

评分
0.5
动能
▲ 0.0
文章
13
来源
4

摘要

如果一篇文章报道了礼来公司在其GLP-1系列药物上的增长，那么它就属于这个叙述。

相关文章

US approves new oral weight-loss pill developed by Eli Lilly

The Guardian · 四月 02, 2026
Mixed

Why Eli Lilly Stock Trounced the Market Today

Nasdaq · 四月 01, 2026
Mixed

Eli Lilly vs Novo Nordisk: Which Obesity Drug Stock Is the Better Buy?

Nasdaq · 三月 27, 2026
Mixed

来源

US approves new oral weight-loss pill developed by Eli Lilly The Guardian
Eli Lilly Is Bringing AI-Developed Drugs to Market. Should You … Yahoo Finance
Why Eli Lilly Stock Trounced the Market Today Nasdaq
FDA approves Eli Lilly's GLP-1 pill, opening the next phase … CNBC
Eli Lilly and Company (LLY) Continued to Gain from Its … Yahoo Finance
Eli Lilly’s (LLY) Shares Up Since Jim Cramer Said He … Yahoo Finance
GSK (GSK) Shares Up Significantly Since Jim Cramer Said to … Yahoo Finance
Mounjaro maker wants NHS drug price rises in return for … The Guardian
Jefferies Remains a Buy on Eli Lilly and Company (LLY) Yahoo Finance
Eli Lilly vs Novo Nordisk: Which Obesity Drug Stock Is … Nasdaq
Hims & Hers Expands Access To Novo Nordisk's FDA-Approved GLP-1 … Nasdaq
Eli Lilly (LLY) Gained From Growth in its GLP-1 Franchises … Yahoo Finance

时间线

最后更新 三月 27, 2026